BPC-157

BPC-157 is a synthetic fragment of body protection compound, a protein sequence identified in human gastric juice. Unlike most peptides of its size it is reported to remain stable in gastric acid, which is why oral routes appear in the literature at all.

The mechanism most consistently described in animal work is angiogenic: BPC-157 appears to promote formation of new blood vessels at injury sites, largely through interaction with the nitric oxide system and upregulation of vascular endothelial growth factor receptor 2 (VEGFR2). Increased blood supply to a healing tendon or ulcer plausibly explains much of the downstream effect.

Secondary mechanisms reported in rodents include modulation of growth hormone receptor expression in fibroblasts, effects on the dopaminergic and serotonergic systems, and increased expression of antioxidant enzymes including heme oxygenase-1.

None of these pathways have been confirmed in humans. They are inferences from animal tissue, and the leap from "raises VEGFR2 in a rat tendon" to "heals a human tendon" is exactly the leap that has not been demonstrated.

In rodent models the findings are unusually consistent across independent groups: accelerated healing of transected Achilles tendon and quadriceps muscle, protection against NSAID-induced gastric lesions, improved outcomes in inflammatory bowel models, and effects on fistula closure.

Human evidence is limited to three small pilot studies — intra-articular injection for knee pain, an interstitial cystitis study, and an intravenous safety and pharmacokinetic study. None reported significant adverse effects, but none were powered to detect efficacy or uncommon harms.

A 2025 systematic review of use in orthopaedic sports medicine and a 2025 narrative review both reached the same conclusion: promising preclinical signal, insufficient human data to support clinical use.

Anecdotal reports of soft-tissue recovery are abundant online and are not evidence. They are uncontrolled, unblinded, and subject to the natural history of injuries that improve on their own.

Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. Once reconstituted it is refrigerated and used within weeks; the lyophilised powder is far more stable and is what long-term storage should preserve.

Subcutaneous injection near the site of interest is the most commonly reported route in community use, on the reasoning that local concentration matters. That reasoning is not established — the systemic angiogenic mechanism described in animal work would not require local administration.

Oral administration appears in the animal literature because of the compound's reported gastric stability, and is the route most often described for gastrointestinal use.

Track the date you reconstitute each vial. The Inventory section does this, and it is the difference between knowing your vial is three weeks old and guessing.

No serious adverse effects have been reported in the three published human pilot studies, and rodent toxicology has not surfaced major concerns at studied doses. This is genuinely reassuring as far as it goes — and it does not go very far.

What that evidence cannot tell you: nothing about long-term use, nothing about population-level rare events, and nothing about interactions. Three small studies is not a safety profile.

The most commonly reported issues in community use are local — injection-site irritation, redness, and transient discomfort. These are consistent with subcutaneous injection generally rather than specific to this compound.

The theoretical concern most worth understanding is the angiogenic mechanism itself. A compound that promotes new blood vessel formation is, in principle, a compound you would not want circulating alongside an undiagnosed tumour, which depends on angiogenesis to grow. This has not been demonstrated as a real-world risk, and it has also not been ruled out, because the studies that would rule it out have not been done.

The most frequently reported pairing is with TB-500 (a thymosin beta-4 fragment), on the theory that the two act on complementary parts of tissue repair — angiogenesis and cell migration respectively. The Wolverine blend in the library is this combination. No controlled study has tested the pair in humans.

Combination use makes attribution impossible. If you run two compounds and something improves, you have learned nothing about which one did it — and if something goes wrong you have the same problem in the opposite direction. Staggering changes is what makes your own logs readable later.

The preclinical body of work is substantial, spanning several decades and dominated by a small number of research groups, primarily in Croatia. That concentration is worth noting: independent replication across unrelated labs is thinner than raw publication count suggests.

Human research consists of three small pilot studies. As of this review there is no completed large randomised controlled trial.

A 2025 systematic review in orthopaedic sports medicine and a 2025 literature and patent review both concluded that the compound remains investigational.

A February 2026 STAT investigation examined the gap between the marketing claims made for BPC-157 and the underlying evidence base, and is worth reading alongside the primary literature.

Not approved by the FDA for any indication. In 2023 the FDA placed BPC-157 in Category 2 of its bulk drug substances list — substances with significant safety risks for use in compounding — which effectively removed it from legal compounding pharmacy supply in the United States. It is widely sold labelled "for research use only, not for human consumption". Status varies by country; check your own jurisdiction rather than assuming.

The World Anti-Doping Agency added BPC-157 to its Prohibited List in 2022. It is not on the current list as of this review date. WADA reissues the Prohibited List each January, so any tested athlete must verify against the live list rather than relying on this page.

BPC-157 has the most interesting preclinical file of any compound in this library and one of the weakest human files. Both things are true at once, and most of the confusion around it comes from people citing the first as though it were the second.

If you use it, understand that you are the study. Log honestly, change one thing at a time, and treat the absence of reported harms as what it is — an absence of data rather than evidence of safety.